AbbVie Inc. (NYSE:ABBV)

Prescription drugs

Major Pharma Short Interest Faces Significant Drop

The short interest data have been released for the August 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
bull and bear

Credit Suisse Issues Top Pharma Picks in Bull/Bear Upside Analysis

It is sometimes hard to wonder about health care and pharmaceutical stocks during an election year. Still, with uncertainty can come opportunity. The team at Credit Suisse has issued its ...
Read Full Story »
Medicine pills

Major Pharma Short Interest Slides

The short interest data have been released for the July 29 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
investing

Jefferies Makes Another Big Summer Change to Its Franchise Picks List

With the second-quarter earnings reporting almost over, and the second half of 2016 well underway, many of the top firms we follow on Wall Street are making some changes to the ...
Read Full Story »
Prescription drugs

Jefferies Keeps Red-Hot Dividend Pharmaceutical Stock as Top Sector Pick

Health care has lagged the top sectors in the S&P 500 over the past year, but it is starting to catch up and some nice moves in the big pharmaceutical ...
Read Full Story »
Female patient on gurney

How AbbVie Won Big on Earnings

AbbVie Inc. (NYSE: ABBV) released its second-quarter earnings report before the markets opened on Friday. The company said that it had $1.26 in earnings per share (EPS) on $6.45 billion ...
Read Full Story »
gas pipeline

Jefferies Makes Key Changes to Top Energy Stocks in Franchise Picks Portfolio

With earnings season winding down, many of the top firms we cover on Wall Street are making some changes to their list of high conviction stocks that they present to ...
Read Full Story »
coins

Bristol-Myers Earnings Don’t Appear to Be Enough for Investors

Bristol-Myers Squibb Co. (NYSE: BMY) released its second-quarter earnings report before the markets opened on Thursday. The company posted $0.69 in earnings per share (EPS) on $4.87 billion in revenue, ...
Read Full Story »
Prescription drugs

Short Sellers Get Selective on Major Pharma

The short interest data have been released for the July 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Medicine pills

Top Analyst Thinks Big Pharmaceutical Stocks Will Outperform the Rest of 2016

Ever since the Hillary Clinton high drug price tweet in September of last year, the major pharmaceuticals and biotechs have struggled, and while performance has improved over the past quarter, ...
Read Full Story »
Apple store

Apple Picked as World’s Favorite Company

In a study that ranks "perceived strength" of companies rather than their financial performance, Apple Inc. (NASDAQ: AAPL) took the top spot. Research firm Future Brand described it selection methodology this ...
Read Full Story »
Profit or Loss

10 Must-See Earnings for the Coming Week

24/7 Wall St. has put together a preview of some of the major companies reporting their quarterly results this week. We are in the heart of earnings season, in which ...
Read Full Story »
Medicine pills

Pharmaceutical Stocks May Be the Best Total Return Play: 3 to Buy Now

If one sector has struggled this year it has been the health care sector, which is surprising given that usually it is considered to be very defensive. But ever since a ...
Read Full Story »
Prescription drugs

Short Sellers Run for Cover From Major Pharma

The short interest data have been released for the June 30 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Prescription drugs

How Major Pharma Is Faring After the Brexit

The broad markets are recovering in the wake of the Brexit and it really appears to be one big head fake. We are also realizing that the Brexit was a ...
Read Full Story »